Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-123M | $-119M | $-101M | -58.5% | - | 23.9% |
| 2024 | $0M | $-102M | $-96M | $-89M | -55.9% | - | 75.3% |
| 2023 | $0M | $-59M | $-55M | $-51M | -39.0% | - | 43.4% |
| 2022 | $0M | $-38M | $-38M | $-35M | -35.4% | - | - |
| 2021 | - | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Operating Expense | 122.76 |
| Research And Development | 81.40 |
| Selling General And Administration | 42.06 |
| Total Expenses | 122.76 |
| Operating Income | -122.76 |
| Total Operating Income As Reported | -123.55 |
| EBITDA | -122.68 |
| Normalized EBITDA | -122.44 |
| EBIT | -122.76 |
| Interest Income | 4.16 |
| Interest Expense | - |
| Net Interest Income | 4.16 |
| Other Income Expense | -0.24 |
| Interest Income Non Operating | 4.16 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | 4.16 |
| Pretax Income | -118.84 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -118.84 |
| Net Income From Continuing And Discontinued Operation | -118.84 |
| Net Income From Continuing Operation Net Minority Interest | -118.84 |
| Net Income | -118.84 |
| Net Income Common Stockholders | -118.84 |
| Net Income Including Noncontrolling Interests | -118.84 |
| Normalized Income | -118.60 |
| Diluted NI Availto Com Stockholders | -118.84 |
| Basic Average Shares | 222.39 |
| Diluted Average Shares | 222.39 |
| Reconciled Depreciation | 0.09 |
| Total Unusual Items | -0.24 |
| Total Unusual Items Excluding Goodwill | -0.24 |
| Special Income Charges | -0.55 |
| Other Special Charges | 0.55 |
| Gain On Sale Of Security | 0.31 |
| Depreciation Amortization Depletion Income Statement | 0.09 |
| Depreciation And Amortization In Income Statement | 0.09 |
| General And Administrative Expense | 42.06 |
| Other Gand A | 42.06 |
| Total Other Finance Cost | - |
| Other Taxes | -0.78 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Savara Inc.this co. | SVRA | $1.1B | -9.14 | 5.35 | -58.5% | -8.83 |
| OPKO Health, Inc. | OPK | $1.1B | -4.88 | 0.87 | -17.8% | -27.38 |
| Aktis Oncology, Inc. | AKTS | $1.1B | -17.25 | -7.52 | 43.6% | -14.83 |
| MannKind Corporation | MNKD | $1.1B | 185.49 | -21.31 | -11.5% | 26.79 |
| Omada Health, Inc. | OMDA | $1.1B | -84.72 | 4.71 |
| - |
| - |
| -5.6% |
| -181.05 |
| Xeris Biopharma Holdings, Inc. | XERS | $1.1B | 1916.51 | 77.56 | 4.0% | 28.56 |
| Collegium Pharmaceutical, Inc. | COLL | $1.1B | 16.86 | 3.51 | 20.8% | 4.10 |
| CONMED Corporation | CNMD | $1.1B | 22.48 | 1.02 | 4.6% | 10.49 |
| Azenta, Inc. | AZTA | $1.1B | -18.88 | 0.61 | -3.2% | 20.85 |
| Peer Median | - | 5.99 | 0.95 | 0.4% | 7.30 | |